Seizert Capital Partners, LLC Eagle Pharmaceuticals, Inc. Transaction History

Seizert Capital Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	BUY	$45.82 - $56.9 $337,693 - $419,353	7,370 New	7,370 $375,000
Q3 2020 Nov 03, 2020	SELL	$37.02 - $51.28 $734,772 - $1.02 Million	-19,848 Closed	0 $0
Q2 2020 Aug 06, 2020	SELL	$43.24 - $55.02 $142,605 - $181,455	-3,298 Reduced 14.25%	19,848 $952,000
Q1 2020 May 05, 2020	SELL	$34.37 - $60.07 $69,771 - $121,942	-2,030 Reduced 8.06%	23,146 $1.07 Million
Q4 2019 Feb 10, 2020	BUY	$54.32 - $64.31 $1.37 Million - $1.62 Million	25,176 New	25,176 $1.51 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Seizert Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Seizert Capital Partners, LLC with notifications on news.